NCT06196762View on ClinicalTrials.gov

Phase I of XKH002 Injection in Patients

PHASE1RecruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

April 1, 2026

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG

XKH002 Injection

240 mg/4 mL/vial（60 mg/mL）

Trial Locations (1)

Unknown

RECRUITING

Peking University Cancer Hospital, Beijing

All Listed Sponsors

lead

Zhejiang Kanova Biopharmaceutical Co., LTD

INDUSTRY